Clinical trial NCT01157052: Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients
Official title: Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Neoplasms, Colorectal
Colorectal Cancer
Colorectal Carcinoma
Keywords: magnesium
calcium
adverse effects
kinetics, drug
Lead sponsor: AHS Cancer Control Alberta
Sponsor class: OTHER
First posted: 2010-07-05
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The investigators hypothesize that Ca2+/MG2+ infusions will not have a significant effect on oxaliplatin pharmacokinetics.

Detailed description: This is a clinical pharmacology prospective non-randomized trial to determine oxaliplatin pharmacokinetics in the presence and absence of calcium and magnesium supplementation.

Eligibility criteria: Inclusion Criteria:

* Patients must have Metastatic Colorectal Cancer (stage IV)
* Patients who were treated with 5FU and leucovorin in the adjuvant setting or with 5FU and leucovorin (LV)or/and FOLFIRI regimen for metastatic setting may be eligible for this trial.
* Patients must be ≥ 18 years
* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
* Patients must have adequate renal function of creatinine \< 1.5mg/dl and a creatinine clearance \> 45ml/min. Patients must have adequate hepatic function with a bilirubin \> 1.5 mg/dl and AST (normal range 0-14/L) and ALT (normal range 0-49 U/L) in the absence of liver metastasis or \</= 5X the upper limit of normal of AST and ALT in the presence of liver metastasis.
* Patients must have adequate bone marrow function with absolute neutrophil count(ANC)≥ 1,500/цl and platelets ≥ 100,000/цl and a hemoglobin ≥ 10g/d.
* Patients must be willing and able to comply with the study protocol for the study duration and patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.
* Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment. Also,women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. The investigator is requested to advise the patient how to achieve an adequate contraception.
* Life expectancy longer that 6 months

Exclusion Criteria:

* Patients who have received oxaliplatin previously
* Patients with known peripheral neuropathy ≥ grade 2 according to the WHO scale
* Patients who have tested positive for HIV
* Patients with other significant medical, psychiatric disorders tha, in the opinion of the investigator, will exclude the patient from the study for compliance of safety reasons.
* Patients who cannot swallow
* History of known allergy to oxaliplatin or other platinum compounds,to 5-FU, to LV, or to any ingredients in the formulations or the containers
* Participation in another clinical trial with any investigational drug within 30 days prior to study screening
* Pernicious anemia or other megaloblastic anemia with vitamin B12 deficiency
* Patient with concomitant treatment with drugs/ingredients reported to have a potential activity to prevent peripheral sensory neuropathy (PSN)
* Patients who haven't successfully completed local therapy for previously treated CNS metastases \& who haven't been discontinued with corticosteroid for \>4kws before starting chemotherapy. Patients with asymptomatic brain mets who have no evidence of midline shift on CT/MRI may be enrolled without initiation of local therapy for the CNS mets. Repeat scan must be performed \< 4wks to ensure no progression.

Primary outcomes:
measure: The primary objective of this study is to determine potential pharmacokinetic interactions between oxaliplatin and calcium and magnesium.
timeFrame: Post cycle 2 and 3
Secondary outcomes:
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: Cross Cancer Institute
state: Alberta
Study officials:
affiliation: Alberta Health services
name: Michael Sawyer, MD
role: STUDY_CHAIR
References: